BIOMAT Database Logo BIOMAT Database Logo

Identification of material with paternal HLA antigen immunoreactivity from purported circulating immune complexes in patients with gestational trophoblastic neoplasia. 1984

S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy

Circulating immune complex(es) (CIC) have been shown to rise progressively only when patients with hydatidiform molar pregnancy enter gonadotropin-documented remission. The CIC in 3 patients with gestational trophoblastic neoplasia (GTN)--1 with hydatidiform mole and 2 with choriocarcinoma--were characterized. Their clinical course was monitored by serial antigen-nonspecific polyethylene glycol (PEG) 6000-CIC assay and simultaneous human chorionic gonadotropin (HCG) assay from presentation until sustained gonadotropin-documented remission. As serial HCG progressively decreased to normal following surgical or chemotherapeutic reduction in tumor burden, PEG-CIC concurrently rose. Serum obtained at or near peak PEG-CIC levels was precipitated by 3.75% PEG 6000 and fractionated by column chromatography on Sephadex G-200 (exclusion limit, greater than 600,000 mol wt) in glycine-HCl and 1 M NaCl buffer at pH 2.8. None of the 5 elution fractions obtained from the 3 patients contained HCG or anti-HCG activity. However, in the hydatidiform molar patient, fractions 1 through 3 (mol wt greater than 67,000--and containing immunoglobulin) were shown to competitively inhibit complement-dependent antibody lysis on 1 of 4 paternal HLA haplotype (AW32) targets. In 2 of the 3 patients studied, low-molecular-weight fractions (not containing immunoglobulin) significantly inhibited reference anti-HLA binding of antisera directed against only 1 of 4 paternal HLA haplotypes. The immunospecificity of this inhibition was confirmed by criss-cross control assays in which elution fractions obtained from both of these patients were tested for inhibition of lymphocytolysis of both sets of paternal lymphocytes. None of these fractions were immunoreactive to maternal HLA haplotypes. Further analysis of serum from the hydatidiform molar patient revealed that no free complement-fixing antibody against paternal antigens could be found by conventional screening assays in unfractionated patient sera. Three of 4 paternal HLA antigens or non-complement-fixing anti-HLA immunoglobulin was detected in unfractionated pretreatment, treatment, and remission sera of the hydatidiform molar patient. Only in this patient's remission sera was unbound AW32 antigen or non-complement-fixing anti-AW32 antibody detected. These data demonstrate the successful characterization of at least 1 specific antigen fractionated from a tumor-associated immune complex. The implication that some patients with GTN may recognize and react to immunogenic paternal HLA antigens as part of their successful response to therapy for trophoblastic tumor is discussed.

UI MeSH Term Description Entries
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D005260 Female Females
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000936 Antigen-Antibody Complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES. Immune Complex,Antigen-Antibody Complexes,Immune Complexes,Antigen Antibody Complex,Antigen Antibody Complexes,Complex, Antigen-Antibody,Complex, Immune,Complexes, Antigen-Antibody,Complexes, Immune

Related Publications

S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Circulating immune complex levels in patients with gestational trophoblastic neoplasia.
July 1982, Journal of the National Cancer Institute,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Current chemotherapeutic management of patients with gestational trophoblastic neoplasia.
January 2011, Chemotherapy research and practice,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Filarial antigen in circulating immune complexes from patients with Wuchereria bancrofti filariasis.
March 1988, The American journal of tropical medicine and hygiene,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia.
January 2008, Histopathology,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Gestational trophoblastic neoplasia in adolescents.
January 2012, The Journal of reproductive medicine,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Hyperthyroidism in gestational trophoblastic neoplasia.
October 1981, Clinical endocrinology,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
High HIV prevalence in gestational trophoblastic neoplasia patients.
January 2024, AIDS (London, England),
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Improving single-agent chemoresistance risk identification in gestational trophoblastic neoplasia.
August 2021, The Lancet. Oncology,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Radiology of gestational trophoblastic neoplasia.
April 2006, Clinical radiology,
S J Lahey, and G Steele, and R Berkowitz, and M L Rodrick, and D S Ross, and D P Goldstein, and N Zamcheck, and R E Wilson, and J M Deasy
Overview of gestational trophoblastic neoplasia.
July 1973, New York state journal of medicine,
Copied contents to your clipboard!